 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

RenovoRx (NASDAQ:RNXT Free Report) had its price target trimmed by Roth Mkm from $14.00 to $13.00 in a report released on Friday, Benzinga reports. The brokerage currently has a buy rating on the stock. RenovoRx Stock Performance NASDAQ:RNXT opened at $1.70 on Friday. The stock has a market cap of $...

RenovoRx (NASDAQ:RNXT) Price Target Cut to $13.00 by Analysts at Roth Mkm

RenovoRx (NASDAQ:RNXT  Free Report) had its target price decreased by Roth Mkm from $14.00 to $13.00 in a research report report published on Friday morning, Benzinga reports. Roth Mkm currently has a buy rating on the stock. RenovoRx Trading Down 6.5 % NASDAQ RNXT opened at $1.72 on Friday. ...

Roth Mkm Trims RenovoRx (NASDAQ:RNXT) Target Price to $13.00

RenovoRx, Inc. (RenovoRx or the Company) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced financial results for the second quarter ended June 30, 2023. We made strong progress this quarter and have continued momentum in our...

RenovoRx Reports Second Quarter 2023 Financial Results and Operational Highlights

RenovoRx GAAP EPS of -$0.22

RenovoRx, Inc. (RenovoRx or the Company) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced that its CEO Shaun Bagai will provide a corporate overview and update at the 43rd Annual Canaccord Genuity Growth Conference on Thursday...

RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference

RenovoRx, Inc. (RenovoRx) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, and Imugene Ltd (Imugene) (ASX: IMU), a clinical-stage immuno-oncology company, today announced a strategic research collaboration to optimize the delivery of Imugenes...

RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP) Platform

RenovoRx, Inc. (NASDAQ:RNXT  Get Free Report) was the recipient of a significant growth in short interest in the month of June. As of June 30th, there was short interest totalling 10,700 shares, a growth of 21.6% from the June 15th total of 8,800 shares. Based on an average daily trading ...

RenovoRx, Inc. (NASDAQ:RNXT) Short Interest Up 21.6% in June

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Creative Medical Technology Holdings (CELZ Research Report), Bo... Analysts have been eager to weigh in on the Healthcare sector with new ratings on Creative Medical Technology Holdings (CELZ Research Report), Boston ...

Analysts Offer Insights on Healthcare Companies: Creative Medical Technology Holdings (CELZ), Boston Scientific (BSX) and RenovoRx (RNXT)

RenovoRx, Inc. (RenovoRx or the Company) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced the appointment of Margaret A. Tempero, M.D., Director, UCSF Pancreas Center and Leader of the UCSF Pancreas Cancer Program, to the Companys...

RenovoRx Appoints Margaret A. Tempero, M.D., to Scientific Advisory Board

RenovoRx, Inc. (RenovoRx or the Company) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced that ROTH Capital will host a Key Opinion Leader (KOL) webcast with Dr. Michael Pishvaian, Principal Investigator of the Phase III TIGeR-PaC...

RenovoRx Announces ROTH Capital Key Opinion Leader (KOL) Webcast on June 15

RenovoRx, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapy platform to deliver chemotherapy. Its therapy platform includes RenovoTAMP, a therapy platform designed for targeted delivery of chemotherapy enabling localized treatment of solid tumors. The company was founded by Ramtin Agah and Kamran Najmabadi in December 2009 and is headquartered in Los Altos, CA.

Watchers	3,102
52-Wk Low	$1.31
52-Wk High	$5.75

Market Cap	$14.22M
Volume (M)	7,348.00
52-Wk High	$5.75
52-Wk Low	$1.31

RNXT RenovoRx Inc

About

Feed

News

Earnings

Fundamentals